Bill Purye🅰️r

@paulpetertak @CandelTx Well done!

Thanks @CandelTx team for amazing job at #AUA26!

@houmanhemmati Love this. Praying you are appointed.

The FDA Commissioner role is open. This is a pivotal moment for American medicine — & for American patients. Here’s what I believe the next Commissioner should stand for. Not as a wish list. As a baseline. 🔬 1. BRING BACK THE ADCOMS — AND MAKE THEM COUNT. Advisory Committee meetings are one of the FDA’s most powerful tools for transparency. They should return in full force. Open. Public. And real. Patients, doctors, scientists, advocates, & skeptics should all be able to speak. But if you want to speak, you fill out a financial conflict-of-interest form under penalty of perjury — & you read it out loud at the podium before you say another word. Every single person. And if the issues are complex and the science requires more than one day, then take the time. Don’t cut people off because the schedule says so. The public deserves to see exactly how these decisions are made. Real transparency builds real trust. ⚖️ 2. STOP ASKING ONLY “IS IT SAFE ENOUGH TO APPROVE?” — START ASKING “WHAT HAPPENS IF WE DON’T?” For rare diseases. For serious conditions with no good options. For patients who don’t have ten years to wait for traditional trials that may never be feasible. Every regulatory decision carries two risks: the risk of approving something, and the risk of not approving it. Both are real. Both affect real people. When traditional gold-standard trials aren’t practical, we should still be able to move with urgency — but only when paired with strong post-approval commitments and rigorous safety monitoring. We can give desperate patients a chance without abandoning scientific integrity. 🇺🇸 3. THE FDA’S ONLY CLIENT IS THE AMERICAN PATIENT. FULL STOP. The FDA exists to serve patients — not outside interests or external pressures of any kind. It must continue protecting the public from products that carry real, known risks but offer no meaningful clinical benefit. At the same time, when there is credible evidence that a treatment can help patients with serious conditions, Americans and their physicians should be trusted to make informed decisions once they have complete and honest information about the risks, benefits, and alternatives. The FDA’s job is to make sure the science is sound and the information is clear. Then let patients and doctors do what’s best for them. These principles matter because the FDA’s decisions affect every family in this country. Note: This is a simple social media post and not a massive policy document. The issues are FAR more nuanced, there are challenges and risks with each of the things I said above, and I recognize that. But it's intended to serve as a discussion starter. We must always strive to improve, and we can when we have open debate and dialogue.

@bullishbruk @DrPatrick @LoriMills4CA42 Lovely

$IBRX ANKTIVA is free at last! This is a big win for cancer patients. @DrPatrick @LoriMills4CA42

@Spaceateer @Reformed_Trader 💯

@Reformed_Trader The only thing that matters is getting sats in the air.

$ASTS daily charts: the key concern is we officially closed below the uptrend from last April. This opens up downside without a quick reclaim or a failure to hold the 175ema and 200sma. This brings into focus the anchored VWAP from last April which sits just above $66, which aligns with my weekly chart level of the weekly 50sma also around $66. There's a trend line on the linear chart that is just below today's close that we tested on Monday's open. If we lose that trend it aligns with another trend also around $66. Since going public, every April has printed an April low that often preceded a strong rally that peaked at the end of June to as late as August. Only in 2022 during the bear market did it take out April's low, but it still rallied far higher by August. The 300EMA currently aligns with the $65/$66 point of interest. With this much confluence both where we closed today and at $66 we have two points of interest that will be very important into next week. Losing last week's low sets it up for a rapid sweep to $66 area imo. How we react at either Monday's low or $65/$66 will determine how deep and how long this correction could last. My lean is a major low will be put in next week or possibly the start of May. Whether that's low to mid $70 or mid $60 probably won't matter by the summer as I still expect this to trade much higher by then. Lastly, it's worth noting that technical levels can undercut and not necessarily invalidate if a reclaim materializes. Have a good weekend! *NFA

@davill @AST_SpaceMobile Let's get this party started

"Never Tell Me The Odds" is back. Team Blue inspected every system, completed refurbishment, and certified it for flight. Proud to put a flight-proven booster to work for @AST_SpaceMobile on NG-3. Enjoy this fun video of us moving the integrated vehicle to the Transporter Erector (TE).

@spacanpanman It can be truly exhausting. Having a healthy perspective along with some good bourbon works pretty well for me...

$ASTS:

@gainzalgo Ah, i got it - you're shorting IBRX.

$IBRX the FDA letter is a hard read, and honestly it feels like a lot of us may have been misled, me included. A lot of claims were repeated with confidence, but now the FDA is laying out specific examples saying the company overstated or misrepresented parts of the science. That deserves real attention, not blind deflection. Wanting a breakthrough in cancer treatment is understandable. That hope pulls people in. It pulled me in too. But this is the point where emotion has to step aside and the actual statements from the FDA need to be examined one by one. Anecdotes are not evidence. Belief is not evidence. And hope is not evidence. If the FDA is right, then this was not just overpromotion. It means people were sold something bigger than what the science actually showed. I hate cancer. That is exactly why the truth matters so much.

@SJCapitalInvest Same exact situation here, brother. Unreal.

@DrMakaryFDA No, you don't appear to be doing that. Instead, you're sending a shameful warning to one of the premier cancer fighting entities. Immunity Bio. Just optics and empty promises. I'd have no problem seeing the FDA disbanded.

We’re delivering for cancer patients who have been waiting for game-changing therapies.

@CharlotteH25311 Work assignment wrapped up. Corporate sent me elsewhere. :-)

@BillPuryear3 Oh that's nice, I think I should know where that is. What made you leave though?

Met @DrJBhattacharya who heads NIH and @DrTonyLetai who heads NCI for the first time. The joy of a deep conversation between true scientists and doctors whose life’s mission is to help our patients and the American people is evident! I truly enjoyed discussing the science underlying our work on IL-15 and the decade of trials we undertook since 2015 in partnership with NCI. Credit to the NCI for identifying IL-15 as the number one ranked cytokine to cure cancer… the report on the table which I shared with these 2 leaders of science was such an open and collaborative discussion. More of such meetings should happen! Science is the true north.

@CharlotteH25311 By the way, Charlotte, I lived and worked near Birmingham for 5 years. My experience there was excellent. I had offices in Oldbury, a factory in Derby, and eventually moved from Four Oaks to da home in the small hamlet of Wall. I miss it.

@BillPuryear3 @DrPatrick @DrJBhattacharya @DrTonyLetai Hurry up and send him a direct message I'm sure he'll help alright? I wish you the best.

@DrMakaryFDA Please hurry up with life-changing and life-saving ANKTIVA! I - and millions of other Americans need it NOW. Please and thank you.... we need your immediate help.

Some FDA decisions are taking WEEKS. Thank you to the dedicated FDA scientists who are making this unprecedented efficiency possible.

@CharlotteH25311 @DrPatrick @DrJBhattacharya @DrTonyLetai Thank you, Charlotte!

@BillPuryear3 @DrPatrick @DrJBhattacharya @DrTonyLetai Dr. Pat Soon-Shiong gave me real hope on glioblastoma when I fell out of options. After consultation his protocol (Bioshield trial + alternative medicine ) changed everything. You might be fortunate enough to get a reply: Patricksoonshiongmd@yahoomail.com

@DrMakaryFDA What on earth is taking you so long for Anktiva? As a 2 x cancer survivor looking for medical hope and REAL, CURATIVE APPROACHES - I do not understand what the FDA's problem is! The rest of the world is getting it, why are you allowing big pharma to dictate my health options?

FDA is setting new records in how rapid we are approving cancer drugs—some are so powerful, they have the potential to bring patients out of hospice.

@FirstSquawk Good.

JPMORGAN CUTS SOME SERVICES FOR CITADEL SECURITIES: FT

Cancer might hate @DrPatrick and $IBRX, but the whole world loves you. @DrMakaryFDA what are you going to do about getting #Anktiva to market for Lymphonenia sooner? Americans are dying because of your indecision.

@adamfeuerstein @DrPatrick What's wrong with you?

Th FDA is absolutely correct, and confirms what I’ve said all along. This $IBRX @DrPatrick “lymphopenia” push means nothing until or unless they come up with real data showing patient benefit. The “number” doesn’t matter.

@DrMakaryFDA Please get Immunity Bio Anktiva approved ASAP to save countless lives!!!

I’ve signed 100% of compassionate use requests that have come to my desk.

@spacanpanman LOLOLOLOL🤣

$ASTS: Starlink head of MNO partnerships begging to stop making their job more difficult